Latest news

• Sanofi said to be looking at options for $30bn consumer health unit

  There have been some failures as well however, such as dengue vaccine Dengvaxia and underperforming cholesterol drug Praluent (alirocumab).

• Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

  Dengue vaccine TAK-003:Takeda’s dengue fever vaccine candidate  TAK-003 hit the efficacy mark in a large-scale study reported earlier this month, and seems to be safe in

• Takeda’s dengue vaccine seems safe with no prior virus exposure

  Appears unaffected by serious safety issue affecting Sanofi rival. Takeda says new data shows its candidate vaccine for dengue fever TAK-003 is effective, and crucially doesn’t seem to be ... The new analysis from the 20, 000-patient TIDES in

• Sanofi’s latecomer PD-1 gets date for FDA verdict

  blockbuster Lantus (insulin glargine) and a poor start for dengue vaccine Dengvaxia.

• Sanofi warns of difficult few months as diabetes sales slump

  Overall, sales for the quarter were down nearly 9% to just under 8bn, with cancer and cardiovascular drugs and vaccines also underperforming, the latter because of the safety problems with dengue ... vaccine Dengvaxia and supply issues for paediatric